BALAXI PHARMACEUTICALS LIMITED

rs,

armaceuticals Limited Chinta Shalini Company Secretary Registered Office: 2" Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-Ill, Hyderabad, Telangana, India - 500096. CIN: L251

58%

Y21 - 100 Mn FY21 - 424 Mn PAT Q4FY21 - 84 Mn FY21 - 381 Mn Pharmaceuticals Business contributes 58% of Revenue Pharmaceuticals Business contributes 73% of EBITDA 556 Product Registrations 119 pen

73%

381 Mn Pharmaceuticals Business contributes 58% of Revenue Pharmaceuticals Business contributes 73% of EBITDA 556 Product Registrations 119 pending approval from Ministry of Health (MOH) for var

18.9%

lidated Financial Highlights In INR Mn Revenue EBITDA & EBITDA Margin PAT & PAT Margin 2,313 18.9% 424 18.3% 15.8% 381 16.5% 530 100 84 Q4 FY21 FY21 Q4 FY21 FY21 Q4 FY21 FY21 The Comp

18.3%

ncial Highlights In INR Mn Revenue EBITDA & EBITDA Margin PAT & PAT Margin 2,313 18.9% 424 18.3% 15.8% 381 16.5% 530 100 84 Q4 FY21 FY21 Q4 FY21 FY21 Q4 FY21 FY21 The Company recorded

15.8%

ighlights In INR Mn Revenue EBITDA & EBITDA Margin PAT & PAT Margin 2,313 18.9% 424 18.3% 15.8% 381 16.5% 530 100 84 Q4 FY21 FY21 Q4 FY21 FY21 Q4 FY21 FY21 The Company recorded a drop

16.5%

n INR Mn Revenue EBITDA & EBITDA Margin PAT & PAT Margin 2,313 18.9% 424 18.3% 15.8% 381 16.5% 530 100 84 Q4 FY21 FY21 Q4 FY21 FY21 Q4 FY21 FY21 The Company recorded a drop in revenue

INR 660 million

100 84 Q4 FY21 FY21 Q4 FY21 FY21 Q4 FY21 FY21 The Company recorded a drop in revenue from INR 660 million in Q3FY21 to INR 530 million in Q4F2, the drop in fourth quarter revenue is normal as China is shut

INR 530 million

FY21 FY21 Q4 FY21 FY21 The Company recorded a drop in revenue from INR 660 million in Q3FY21 to INR 530 million in Q4F2, the drop in fourth quarter revenue is normal as China is shut down for most of the quarter

25.6%

preciation Finance Cost PBT Tax Expense PAT PAT Margin % FY21 2,313 22 2,336 1,721 592 25.6% 85 83 424 521 15 536 392 128 603 16 619 455 148 660 7 667 495 165 530 -3 527

24.6%

424 521 15 536 392 128 603 16 619 455 148 660 7 667 495 165 530 -3 527 378 151 24.6% 24.5% 24.9% 28.6% 19 19 90 21 24 103 22 27 116 23 25 100 17.3% 17.1% 17.5% 18.9%

24.5%

1 15 536 392 128 603 16 619 455 148 660 7 667 495 165 530 -3 527 378 151 24.6% 24.5% 24.9% 28.6% 19 19 90 21 24 103 22 27 116 23 25 100 17.3% 17.1% 17.5% 18.9% 18.3%

“Mission To establish strong portfolios of pharmaceuticals formulations registrations and strong channel networks in each market we target, we are also building a branded consumer products business which complements our pharmaceuticals business and provides us operating leverage on the back of our well-established on-ground infrastructure and commercial relationships.”

“Tapping strong yet fragmented markets, which are difficult to enter Leveraging the strengths of on-ground presence & distribution network Starting with establishing operations in Angola with strong and robust on-ground infrastructure with warehouses, fleet and personnel, we have replicated this model successfully in Guatemala and Dominican Republic and working on replicating this model in other target geographies.”

“» The Company files technical dossier for product registrations in target markets.”

“» With a growing brand penetration in Venezuela, among the top 3 markets by size in Latin America, we now aim to create in-roads in this region as well.”

“Asset-Light Production Once identified, we develop our products by working with reliable outsourcing partners for high quality and reliability and registering these products within our respective multiple target markets.”

“It has also set its eyes on entering additional markets in Africa (similar characteristics to Angola) and Latin America in the medium term.”

“• Guatemala is the biggest pharmaceuticals market in Central America and expected to grow at 8.1% CAGR to reach US$1.5 billion by 2021.”

Balaxi Pharmaceuticals

4

Pharma Product Portfolio

4

Pharmaceuticals Business

4

Our Genesis

2

How We Operate

2

Investing In Balaxi

2

Strong Management

2

Strong Governance

2

Registered Office

1

Key Criteria for Market Selection

1

Registered Office

2" Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-Ill, Hyderabad, Telangana, India - 500096. CIN: L25191TG1942PLC1215¢8 Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in (Formerly known as Balaxi Ventures Lirr ted) Page - 01 B A L A X I P H A R M A C E U T I C A LS L I M I T E D INVESTOR PRESENTATION Page - 02 B A L A X I P H A R M A C E U T I C A LS L I M I T E D Disclaimer This presentation and the following discussion may contain “forward-looking statements” by “Balaxi Pharmaceuticals Limited” that are not historical in nature. Such forward-looking statements are subject to certain risks and uncertainties such as government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. “Balaxi Pharmaceuticals Limited” will not be in any way be responsible for any action taken based on

Balaxi Pharmaceuticals

Bridging the supply chain gap in frontier markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D We are a branded IPR-based pharmaceuticals Company focusing on frontier markets, with a vast and growing portfolio of drugs across multiple therapeutic segments. Vision To be amongst top two generic pharmaceuticals players in multiple global frontier markets, giving us scale, market homogeneity, healthy margins and quality growth where value and volume are both established in a balanced way. Mission To establish strong portfolios of pharmaceuticals formulations registrations and strong channel networks in each market we target, we are also building a branded consumer products business which complements our pharmaceuticals business and provides us operating leverage on the back of our well-established on-ground infrastructure and commercial relationships. Page - 14

Balaxi Pharmaceuticals

Bridging the supply chain gap in the frontier markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D Our value system is the foundation for transparency and strong corporate governance. While we create value for shareowners, we work ethically and honestly to positively impact all our stakeholders sustainably. Values » Customer Centricity » Quality Products » Professional Approach » Best-in-Class Business Practices Purpose To bring high-quality every-day medicines within the reach of populations in promising frontier markets, thus creating sustainable value for our stakeholders. Page - 15

Balaxi Pharmaceuticals

Global Presence With Localisation B A L A X I P H A R M A C E U T I C A LS L I M I T E D A growing pharmaceuticals company with on-ground presence in markets within Africa, Caribbean Islands & Latin America Headquartered in Hyderabad, India, we are an IPR-driven asset-light pharma company with a distinct produce, stock & sell model, supplying branded and generic medicines in chosen markets. Tapping strong yet fragmented markets, which are difficult to enter Leveraging the strengths of on-ground presence & distribution network Starting with establishing operations in Angola with strong and robust on-ground infrastructure with warehouses, fleet and personnel, we have replicated this model successfully in Guatemala and Dominican Republic and working on replicating this model in other target geographies. Balaxi Pharmaceuticals Limited Amongst the top two generic pharma players in our chosen markets, successfully leveraging our infrastructure and relationships to exploit opportunities in br

Our Genesis

The Company’s Evolution B A L A X I P H A R M A C E U T I C A LS L I M I T E D Pre 2017 » The Company was listed on NSE in 2015 as ‘The Anandam Rubber Company Ltd’ 2020-2021 » The Company received an approval for change of name from ‘Balaxi Ventures Ltd.’ to ‘Balaxi Pharmaceuticals Ltd’, in line with the predominant focus on the Pharma vertical. » The Company began progressively consolidating various well- established businesses of the Balaxi Group. » Balaxi now has in its fold a rich portfolio of 556 pharmaceuticals product registrations, strong distribution strength of 40 warehouses and a fleet of owned vehicles across 3 countries. 2017-2019 » In March, 2017, the Company was taken over by Balaxi Group, a prominent pharmaceuticals player in Angola. » Subsequently, the name of the Company was changed to ‘Balaxi Ventures Limited’. » By 2019, Balaxi Group had extended its pharmaceuticals business presence to, Guatemala, and Dominican Republic as well. Page - 17

Our Genesis

Balaxi Group’s Journey B A L A X I P H A R M A C E U T I C A LS L I M I T E D 2003-07 2008-10 2011-13 2014-16 2017-19 2020-2021 » Commenced Pharmaceuticals business by supplying white labelled products to customers in Africa. » Sourcing was from WHO GMP certified plants based in India. » Created front-end presence for its Pharmaceuticals business by setting up 1st wholesale depot in Angola in 2008. » Started sourcing pharmaceuticals from WHO GMP certified manufacturers in China by setting up an office in China in 2011. » Opened first wholesale depot for its ancillary business in Angola. » In 2014, the Group expanded its pharma business in Angola by setting up its 12th wholesale depot and a central distribution warehouse. » Made in-roads in the Dominican Republic pharmaceuticals market, submitted technical dossiers for securing product registrations and opened a central distribution warehouse. » Setup central distribution warehouse in Guatemala marking the entry of BALAXI into its third